Identifying optimal candidates of transarterial chemoembolization (TACE) vs. sorafenib in patients with unresectable hepatocellular carcinoma

BACKGROUND: Sorafenib has been recommended as the first-line treatment and shown to prolong median overall survival (OS) of patients with advanced unresectable hepatocellular carcinoma (HCC). Recently, a growing amount of research has supported the application of transarterial chemoembolization (TAC...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Shoujie, Dou, Weijia, Fan, Qingling, Hu, Jie, Li, Huichen, Zhang, Xiangnan, Zhang, Qian, Liu, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290559/
https://www.ncbi.nlm.nih.gov/pubmed/32566614
http://dx.doi.org/10.21037/atm.2020.02.123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290559/
https://www.ncbi.nlm.nih.gov/pubmed/32566614
http://dx.doi.org/10.21037/atm.2020.02.123

Ejemplares similares